丹麦IgA肾病二十年:发病、治疗与预后变化
该研究基于丹麦全国登记数据,纳入2002–2023年1298例活检确诊的成人IgA肾病患者,评估发病、患病、治疗及预后变化。
要点
- 诊断时中位eGFR 60 ml/min/1.73 m2,中位uACR 1.2 g/g。
- 15年KFRT风险42.7%,全因死亡22.8%,二十年预后无实质改善。
核心结论
- 丹麦IgA肾病年发病率在研究期间增长三倍。
- 活检时多数患者肾功能保留但存在显著白蛋白尿。
- KFRT和死亡风险显著,且过去二十年预后整体未改善。
研究设计与样本
- 基于人群的队列研究,纳入丹麦2002–2023年所有活检确诊的成人IgA肾病患者,共1298例。
- 使用丹麦健康登记数据获取医院诊断、药物治疗和实验室结果。
- 研究期分为三个日历时段,计算粗率和年龄性别标准化发病率及患病率。
主要发现
- 诊断时中位eGFR为60 ml/min/1.73 m2(IQR 40–85),中位uACR为1.2 g/g(IQR 0.6–2.2)。
- 15年KFRT风险为42.7%(95%CI 38.4–46.9),15年全因死亡为22.8%(95%CI 19.4–26.4)。
- 研究期间5年KFRT或死亡风险无实质变化。
关键数值与推荐
- 肾素-血管紧张素系统抑制剂是诊断后的主要治疗,皮质类固醇使用在整个期间下降。
- 研究期间年发病率增长三倍。
临床怎么用
- 丹麦数据显示IgA肾病即使诊断时肾功能保留,长期肾衰竭和死亡风险仍高。
- RAS抑制剂为主要治疗,激素使用减少,但预后未改善,提示需更有效治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis; however, reported incidences and prevalences vary substantially across countries. This study assessed the epidemiology of IgAN including changes in incidence, prevalence, treatment, and prognosis in Denmark during 2002-2023. METHOD: This population-based cohort study included all adult patients with a biopsy-verified diagnosis of IgAN in Denmark over 22 years. Danish health registries with data on hospital diagnoses, pharmacological therapy, and laboratory results were used. The study period was divided into three calendar periods. Crude and age- and sex-standardized incidence rates and prevalences of IgAN in the Danish population were computed. The period specific 5-year and the overall 15-year cumulative incidence (risk) of kidney failure with replacement therapy (KFRT) and of all-cause death (mortality) were estimated. RESULTS: The study population included 1298 incident adult patients with IgAN. The overall incidence of IgAN was 13.1 per 1 000 000 person-years (95% CI 9.8-16.5). The annual incidence increased threefold during the study period. The prevalence reached 261 per 1 000 000 people in year 2023 (95% CI 246-275). Median eGFR was 60 ml/min/1.73 m2 (IQR 40-85) and median uACR was 1.2 g/g (IQR 0.6-2.2) at time of diagnosis. Following diagnosis, renin-angiotensin system inhibitors constituted a mainstay of treatment while corticosteroid use declined throughout the period. The 15-year risk of KFRT was 42.7% (95% CI 38.4-46.9). The 15-year all-cause mortality was 22.8% (95% CI 19.4-26.4). There were no substantial changes in the 5-year risk of KFRT or mortality during the study period. CONCLUSION: The annual incidence of IgAN in Denmark increased during the study period. At the time of biopsy, many patients had preserved kidney function and substantial albuminuria. The risk of KFRT and mortality was substantial and, overall, the prognosis for Danish IgAN patients did not improve over the past two decades.
引用
- Ystrøm IK, Jensen SK, Andersen IT, et al. IgA nephropathy occurrence, treatment, and prognosis in the last two decades in Denmark. Nephrol Dial Transplant. 2026. PMID: 41649428. doi:10.1093/ndt/gfag021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。